Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

BMC Infectious Diseases

Table 4 Eligibility for Short Course Regimen by Clinical Criteria and DST Performed. c. Participants with Pulmonary MDR-TB Eligible for Short Course Treatment with < 1 Month of MDR-TB Treatment, by DST Performed

Resistance Status	Xpert Only, N = 175	2nd-Line LPA Only,^a N = 146	Testing R, FQ, INJ, Z, and E, N = 140^b	Testing R, FQ, INJ, Z, E, Eto, and Cfz, N = 136^b
	# Eligible or Resistant / # Tested (%)^c	# Eligible or Resistant / # Tested (%)^c	# Eligible or Resistant / # Tested (%)^c	# Eligible or Resistant / # Tested (%)^c
Eligible for Short Course	175 / 175 (100)	46 / 146 (31.5)	9 / 140 (6.4)	8 / 136 (5.9)
Resistant to FQ or INJ	N/A	100 / 146 (68.5)	95 / 140 (67.9)	93 / 136 (68.4)
Resistant to Z or E	N/A	N/A	128 / 140 (91.4)	124 / 136 (91.2)
Resistant to FQ, INJ, Z, or E	N/A	N/A	131 / 140 (93.6)	127 / 136 (93.4)
Resistant to FQ, INJ, Z, E, Eto, or Cfz	N/A	N/A	N/A	128 / 136 (94.1)

^a2^nd-line LPA tests for susceptibility to isoniazid, rifampin, fluoroquinolones, and 2nd-line injectables (amikacin, capreomycin, or kanamycin)
^bR rifampin, FQ fluoroquinolone, INJ 2nd-line injectable, Z pyrazinamide, E ethambutol, Eto ethionamide, Cfz clofazimine
^cPercentages reported reflect number of participants with resistance or susceptibility divided by number of participants who completed susceptibility testing for each drug. As a result, the number of participants in the denominator is not the same in all rows

ISSN: 1471-2334